HIV-1 load quantitation: A 17-year perspective

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 1, 2006, Pages

  Holodniy, Mark ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

CLINICAL PRACTICE; CONFERENCE PAPER; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG POTENCY; DRUG USE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT INDICATION; VIRUS DIAGNOSIS; VIRUS LOAD;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD;

EID: 33748846787     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505352     Document Type: Conference Paper

References (69)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-91.
2. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295:517-22.
3. Ou CY, Kwok S, Mitchell SW, et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988; 239:295-7.
4. De Rossi A, Amadori A, Chieco-Bianchi L, et al. Polymerase chain reaction and in-vitro antibody production for early diagnosis of paediatric HIV infection. Lancet 1988; 2:278.
5. Laure F, Courgnaud V, Rouzioux C, et al. Detection of HIV1 DNA in infants and children by means of the polymerase chain reaction. Lancet 1988; 2:538-41.
6. Hart C, Schochetman G, Spira T, et al. Direct detection of HIV RNA expression in seropositive subjects. Lancet 1988; 2:596-9.
7. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321:1621-5.
8. Ehrnst A, Sonnerborg A, Bergdahl S, Strannegard O. Efficient isolation of HIV from plasma during different stages of HIV infection. J Med Virol 1988; 26:23-32.
9. Holodniy M, Katzenstein DA, Sengupta S, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991; 163:862-6.
10. Lazarus LH, Kitron N. Inhibition and dissociation of mammalian polymeric DNA polymerase by heparin. Arch Biochem Biophys 1974; 164: 414-9.
11. Brennessel BA, Buhrer DP, Gottlieb AA. Use of insoluble heparin for isolation of DNA polymerase enzymes from murine myeloma. Anal Biochem 1978; 87:411-7.
12. Golomb M, Vora AC, Grandgenett DP. Purification of reverse transcriptase from avian retroviruses using affinity chromatography on heparin-sepharose. J Virol Methods 1980; 1:157-65.
13. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991; 29:676-9.
14. Semple M, Loveday C, Weller I, Tedder R. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol 1991; 35:38-45.
15. Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest 1991; 88:1755-9.
16. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis 1991; 164:769-72.
17. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993; 167:798-802.
18. Merigan TC. Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. J Reprod Immunol 1998; 41:177-85.
19. Kuritzkes DR. Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction. J Infect Dis 2004; 190:2047-54.
20. Relucio K, Holodniy M. HIV-1 RNA and viral load. Clin Lab Med 2002; 22:593-610.
21. Stevens W, Wiggill T, Horsfield P, Coetzee L, Scott LE. Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. J Virol Methods 2005; 124:105-10.
22. Berger A, Scherzed L, Sturmer M, Preiser W, Doerr HW, Rabenau HF. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor U1-trasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J Clin Virol 2005; 33: 43-51.
23. de Mendoza C, Alcami J, Sainz M, Folgueira D, Soriano V. Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma. J Clin Microbiol 2002; 40:1518-21.
24. Muller Z, Stelzl E, Bozic M, Haas J, Marth E, Kessler HH. Evaluation of automated sample preparation and quantitative PCR LCx assay for determination of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2004; 42:1439-43.
25. Abravaya KBR, Cloherty G, Erickson D, et al. Performance evaluation of an automated quantitative HIV-1 test: the Abbott RealTime HIV-1 assay [abstract MoPe15.2C03]. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro, Brazil). Geneva: International AIDS Society, 2005.
26. Greengrass VL, Turnbull SP, Hocking J, et al. Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res 2005; 3:183-90.
27. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol 2005; 43:857-61.
28. Malmsten A, Shao XW, Aperia K, et al. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2003; 71:347-59.
29. Malmsten A, Shao XW, Sjodahl S, et al. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2005; 76:291-6.
30. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J Clin Microbiol 2000; 38:323-6.
31. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-9.
32. Salimnia H, Moore EC, Crane LR, Macarthur RD, Fairfax MR. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) standard and ultrasensitive assays caused by freezing patient plasma in centrifuged Becton-Dickinson VACUTAINER brand plasma preparation tubes. J Clin Microbiol 2005; 43:4635-9.
33. Alvarez-Arnao D LA, Canedo B, Baleeiro C. HIV RNA measurement using EDTA or PPT tubes results in different degrees of undetectability [abstract MoPe15.2C06]. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro, Brazil). Geneva: International AIDS Society, 2005.
34. Elbeik T, Nassos P, Kipnis P, Haller B, Ng VL. Evaluation of the VACUTAINER PPT plasma preparation tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2005; 43:3769-71.
35. Holodniy M, Margolis D, Carroll R, Todd J, Mole L. Quantitative relationship between platelet count and plasma virion HIV RNA. AIDS 1996; 10:232-3.
36. Hess C, Klimkait T, Schlapbach L, et al. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002; 359:2230-4.
37. Sabino EC, Gaburo N Jr, Leite JP, Viecili M, Rosenfeld LG. Platelets may affect detection and quantitation of HIV RNA in plasma samples with low viral loads. J Acquir Immune Defic Syndr 2004; 37:1432-3.
38. Holodniy M, Mole L, Yen-Lieberman B, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol 1995; 33:1562-6.
39. Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol 2003; 41:1888-93.
40. Lloyd RBD, Thompson AM, Mathis RL, et al. Comparison of HIV-1 viral load and resistance genotyping between frozen plasma and a novel dried plasma transportation matrix [abstract]. Antivir Ther 2004; 9: S121.
41. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents-April 07, 2005. Bethesda, MD: US Department of Health and Human Services, 2005.
42. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-83.
43. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-29.
44. Miller LG, Golin CE, Liu H, et al. No evidence of an association between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis 2004; 189:1487-96.
45. Alatrakchi N, Duvivier C, Costagliola D, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 2005; 19:25-33.
46. Kaplan SS, Ferrari G, Wrin T, et al. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Res Hum Retroviruses 2005; 21:13-6.
47. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37:1147-54.
48. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS 2004; 18:2419-23.
49. + cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-64.
50. Smith CJ, Staszewski S, Sabin CA, et al. Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr 2004; 37:1155-9.
51. Atlas A, Granath F, Lindstrom A, Lidman K, Lindback S, Alaeus A. Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res Hum Retroviruses 2005; 21:221-7.
52. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age: results from the French Hospital Database on HIV. AIDS 2004; 18:2029-38.
53. Monpoux F, Tricoire J, Lalande M, Reliquet V, Bebin B, Thuret I. Treatment interruption for virological failure or as sparing regimen in children with chronic HIV-1 infection. AIDS 2004; 18:2401-9.
54. Fischer M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003; 17: 195-9.
55. + T-cell counts in patients with chronic HIV infection. J Med Virol 2005; 76:1-6.
56. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5.
57. + lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003; 26:101-7.
58. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis 2005; 40:1350-4.
59. Reger MA, Martin DJ, Cole SL, Strauss G. The relationship between plasma viral load and neuropsychological functioning in HIV-1 infection. Arch Clin Neuropsychol 2005; 20:137-43.
60. Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:167-73.
61. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-77.
62. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191:4-10.
63. Lopez Calvo S, Vela A, Castro A, et al. GB virus C: lack of association with transaminases levels, CD4 and HIV viral load in AIDS patients [in Spanish]. An Med Interna 2003; 20:175-8.
64. Day JH, Grant AD, Fielding KL, et al. Does tuberculosis increase HIV load? J Infect Dis 2004; 190:1677-84.
65. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22:2006-12.
66. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-65.
67. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
68. Ven PV, Mao L, Fogarty A, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19:179-84.
69. Munoz-Laboy M, Castellanos D, Westacott R. Sexual risk behaviour, viral load, and perceptions of HIV transmission among homosexually active Latino men: an exploratory study. AIDS Care 2005; 17:33-45.